Navigation Links
Key mechanism for the proliferation of Epstein-Barr virus discovered
Date:1/14/2010

The Epstein-Barr virus (EBV), a virus of the herpes family, has two distinct life phases: After infecting a cell it first goes into a resting phase. Under certain circumstances the virus can become active and then induces tumor growth or promotes its synthesis in the cell. Especially in patients with weakened immune systems, EBV can cause its host cells to divide uncontrollably causing a tumor to develop.

The causes for the transition of EBV from the quiescent phase to an active mode particularly with respect to the responsible factors and to how the molecular mechanisms function have until now remained elusive. With their findings, the scientists at Helmholtz Zentrum Mnchen have discovered how the virus terminates latency and activates its synthesis in the infected cells.

Professor Wolfgang Hammerschmidt, head of the Department of Gene Vectors at Helmholtz Zentrum Mnchen, explained: "We have now identified the crucial function of the viral BZLF1 protein: It activates the genes of EBV, which are essential for the proliferation of virus particles." About 70 different genes are switched off during the latent phase because certain DNA segments are chemically modified: Some DNA building blocks carry methyl groups. They are a kind of stop signal for the cell apparatus, so that these genes cannot be converted into protein.

"BZLF1 can detect these methylation patterns in the DNA," said Markus Kalla, lead author of the study. With its DNA binding domain, the protein binds directly to the methylated DNA sequence. A second domain of BZLF1 is responsible for the reactivation of the gene. "Such a mechanism was not known before," Wolfgang Hammerschmidt said. Previous research assumed that the methyl groups had to be removed from the DNA building blocks before the transcription factors could bind to the regulatory DNA sequence and thus activate the gene.

The researchers' findings indicate that BZLF1 avoids this hurdle. Accordingly, BZLF1 appears to be essential for establishing and maintaining latency, but also for escaping from it.

During viral synthesis a large number of new particles are usually formed within the cell. To achieve this, viruses use large portions of the cell apparatus, in particular specific proteins and factors. After progeny synthesis the new viruses are released researchers speak of a lytic cycle. The disadvantage: the viruses thus attract the attention of the immune system, which then fights against the pathogen and destroys the cell supporting viral synthesis.

However, the Epstein-Barr virus uses another strategy. Instead of putting all of its energy into immediate synthesis of progeny in the infected cell, it goes into a resting phase following the infection and thus prevents a reaction of the immune system. The virus infects cells of the immune system - the so-called B cells - first inserting its DNA into their cell nucleus. Whereas most viruses immediately start their lytic proliferation cycle and thus use the cell apparatus to replicate the DNA and to generate important structural proteins from the genes, EBV drives transformation of merely a few genes from the cell into proteins. These so-called latent genes are important for the quiescent phase: They see to it that the DNA of the Epstein-Barr virus remains stable in the cell nucleus while the cell itself proliferates. This seemingly peaceful co-existence ends when the virus goes into the lytic phase or induces tumor growth.

These findings published in PNAS by Wolfgang Hammerschmidt and his colleagues constitute an important step for a better understanding of the role of EBV in tumor growth.


'/>"/>

Contact: Sven Winkler
presse@helmholtz-muenchen.de
49-893-187-3946
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. Discovery of a new molecular mechanism that guides visual nerves towards the brain
2. U of Alberta researchers find mechanism that could prevent or treat deadly peroxisome diseases
3. Seeing how evolutionary mechanisms yield biological diversity
4. IUPUI researchers tackle protein mechanisms behind limb regeneration
5. Newly discovered mechanism allows cells to change state
6. New understanding about mechanism for cell death after stroke leads to possible therapy
7. Biologists discover bacterial defense mechanism against aggressive oxygen
8. New research into the mechanisms of gene regulation
9. New mechanism explains how the body prevents formation of blood vessels
10. Texas A&M researchers find new mechanism for circadian rhythm
11. Mechanism for potential Friedreichs ataxia drug uncovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
(Date:2/23/2017)... 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology ... today announced that Linda Marbán, Ph.D, president and chief executive ... Cowen and Company 37th Annual Health ... Boston, MA 29th ... PT (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology: